Alternatives to Rinvoq XR If You Can't Fill Your Prescription

When insurance denies your Rinvoq XR (upadacitinib) prescription or you're caught in a prior authorization delay, you may need an alternative therapy to manage your condition in the meantime — or even long-term. The good news is that there are several solid alternatives in the same drug class and beyond. Here's what to discuss with your doctor.

Other JAK Inhibitors (Same Drug Class as Rinvoq XR)

Rinvoq XR belongs to the JAK inhibitor class — oral small-molecule drugs that block Janus kinase enzymes involved in inflammation. Other FDA-approved JAK inhibitors may be options depending on your diagnosis:

Xeljanz / Xeljanz XR (Tofacitinib)

Tofacitinib (Xeljanz) was the first JAK inhibitor approved by the FDA for rheumatoid arthritis, in 2012. It's approved for RA, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis — overlapping significantly with Rinvoq XR's indications. Tofacitinib is a pan-JAK inhibitor (JAK1/JAK3) compared to Rinvoq XR's JAK1 selectivity. It is available in immediate-release (5 mg twice daily) and extended-release (11 mg once daily) forms. Generic versions of tofacitinib are now available, potentially making it significantly more affordable than Rinvoq XR.

Best for: RA, PsA, UC, AS — when cost or insurance coverage of Rinvoq XR is the primary barrier.

Olumiant (Baricitinib)

Baricitinib (Olumiant) is a JAK1/JAK2 inhibitor approved for rheumatoid arthritis and atopic dermatitis in adults. It's taken once daily (2 mg or 4 mg) and has a safety profile similar to other JAK inhibitors. Clinical studies show baricitinib is therapeutically equivalent to upadacitinib in RA for most patients. It carries the same class-wide boxed warnings (serious infections, MACE, thrombosis, malignancy).

Best for: RA and atopic dermatitis when Rinvoq XR isn't accessible.

Cibinqo (Abrocitinib)

Abrocitinib (Cibinqo) is a JAK1-selective inhibitor specifically approved for moderate-to-severe atopic dermatitis in adults. Like Rinvoq XR, it's taken once daily. If your Rinvoq XR is primarily for atopic dermatitis, abrocitinib is a close alternative.

Best for: Atopic dermatitis specifically.

Biologic Alternatives: TNF Inhibitors

Biologics are injectable medications that target specific parts of the immune system. They work differently than JAK inhibitors but treat many of the same conditions:

Humira (adalimumab) — TNF inhibitor; approved for RA, PsA, AS, UC, Crohn's, and more. Biosimilars available (Hadlima, Cyltezo, Yusimry) at significantly lower cost.

Enbrel (etanercept) — TNF inhibitor for RA, PsA, AS; biosimilar (Eticovo) available.

Remicade (infliximab) — IV infusion TNF inhibitor for RA, UC, Crohn's, AS, PsA; multiple biosimilars available.

Biologic Alternatives for Atopic Dermatitis

If Rinvoq XR was prescribed for atopic dermatitis (eczema):

Dupixent (dupilumab) — IL-4/IL-13 inhibitor; first-choice biologic for moderate-to-severe atopic dermatitis; biweekly injection. Often better covered by insurance than Rinvoq XR for AD.

Adbry (tralokinumab) — IL-13 inhibitor; biweekly injection for moderate-to-severe AD.

Biologic Alternatives for IBD (UC and Crohn's Disease)

If Rinvoq XR was prescribed for ulcerative colitis or Crohn's disease:

Stelara (ustekinumab) — IL-12/23 inhibitor; approved for Crohn's and UC; biosimilars available.

Skyrizi (risankizumab) — IL-23 inhibitor; approved for Crohn's and UC; once-daily maintenance dosing after induction infusions.

Entyvio (vedolizumab) — gut-selective integrin inhibitor; approved for UC and Crohn's with a favorable safety profile.

How to Discuss Alternatives With Your Doctor

When you contact your prescriber about alternatives, be prepared to share:

Why Rinvoq XR isn't accessible (cost, PA denial, pharmacy issues)

Your specific diagnosis and disease severity

Prior medications you've tried and how they worked

Your preference for oral vs. injectable medication

Also read: Why is Rinvoq XR so hard to find? [Explained for 2026]

Important Safety Note

Never stop taking Rinvoq XR or switch medications without talking to your doctor first. Abruptly stopping an immunomodulator can cause a flare of your underlying condition. All JAK inhibitors share the same class-wide boxed warnings, so switching within the class doesn't eliminate the primary safety risks — it just changes the specific drug profile. Your prescriber needs to evaluate which alternative is safest given your individual health history.